Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT04996914 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma

ASTrH
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection or orthotopic liver transplant.

NCT ID: NCT04995016 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

PANDORA
Start date: August 20, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of pembrolizumab combined with axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal cell carcinoma.

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT04984018 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of chidamide plus camrelizumab as second-line therapy for advanced esophageal squamous cell carcinoma treated with PD-1 blockade

NCT ID: NCT04976478 Not yet recruiting - Clinical trials for Cervical Squamous Cell Carcinoma

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Start date: July 2021
Phase:
Study type: Observational [Patient Registry]

To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma

NCT ID: NCT04962958 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label,multi-center ,non-randomized ,single arm exploratory study . This clinical study is an investigator-initiated clinical trial(IIT ). The objective of this study is to evaluate if the addition of hepatic artery infusion chemotherapy (HAIC) and Donafenib after curative resection for hepatocellular carcinoma patients with a solitary tumor≥5 cm and microvascular invasion (MVI) will prevent or delay the recurrence of the disease.

NCT ID: NCT04961138 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma Stage III

Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma

Start date: August 2021
Phase: N/A
Study type: Interventional

The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.

NCT ID: NCT04958473 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer

SAARCC
Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

In patients with recurrent or metastatic renal cell carcinoma, a preliminary evaluation of the safety and efficacy of sintilimab combined with axitinib in patients with advanced renal cell carcinoma was conducted.Progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and disease remission rate (ORR) were evaluated.

NCT ID: NCT04955886 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: August 2021
Phase: Phase 2
Study type: Interventional

A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

NCT ID: NCT04955119 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Fusion Imaging Contrast-enhanced Ultrasound LI-RADS

Start date: July 30, 2021
Phase: N/A
Study type: Interventional

CEUS LI-RASD apply to lesion visible at precontrast ultrasound but not the lesion invisible. Fusion imaging can use to invisible lesions at precontrast ultrasound in clinical practice. Thus, our aim is to explore the application value of CEUS LI-RADS in contrast-enhanced fusion imaging for focal liver lesions that are not visible on conventional ultrasound in high-risk patients with hepatocellular carcinoma.